Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Myelodysplastic Syndromes 1Muscle Invasive Bladder Cancer 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumours 1Advanced Solid Malignancies 1

Interventions

Cytarabine 147Azacitidine 100venetoclax 95Cyclophosphamide 70fludarabine 69Decitabine 63fludarabine phosphate 55Specimen Handling 37Filgrastim 35Daunorubicin 35Mitoxantrone 30Idarubicin 29Etoposide 27Biopsy 26Injections 25Granulocyte Colony-Stimulating Factor 25Busulfan 22Tacrolimus 21Clofarabine 21Mycophenolic Acid 18Melphalan 18Methotrexate 17Bortezomib 17Whole-Body Irradiation 16Stem Cell Transplantation 16Peripheral Blood Stem Cell Transplantation 16Vorinostat 15Gemtuzumab 15Lenalidomide 14decitabine and cedazuridine drug combination 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid, Acute × danvatirsen × Clear all
NCT05986240 2025-11-10

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Montefiore Medical Center

Phase 1 Recruiting
38 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡